A hemodialysis bloodline system is a type of tubing system that connects a patient’s blood circulation to a dialyzer in the course of the dialysis treatment. Hemodialysis is a treatment process for renal failure patients. In the process, the patient’s blood flows through a disposable bloodline into a special filter known as the dialyzer, which filters the blood, removes waste products, adds anti-coagulants, and returns the purified blood back into the patient’s body. There has been a rapid increase in the number of renal patients throughout the world, boosting demand for hemodialysis bloodline systems. These systems offer both biocompatibility and safety & efficiency. Chronic kidney disease (CKD) is a major risk multiplier factor for cardiovascular disease, diabetes, hypertension, inflammatory disease of the kidneys (glomerulonephritis), and aging. CKD may lead to kidney injury and sometimes to complete loss of kidney function, thus leading to renal replacement therapy. World Kidney Day, a global awareness campaign, estimated that 10% of the world’s population is affected by CKD. CKD stood 18th in the global list of causes of total number of deaths in 2010, according to the Global Burden Study. CKD leads to end-stage renal disease (ESRD) if untreated.
It is estimated by the National Kidney Foundation that every year, more than 450,000 ESRD patients are on dialysis in the U.S. alone. Thus, dialysis is the most easily available treatment for kidney disease, and high global prevalence of CKD is a major factor that drives the hemodialysis bloodline systems market. Rapidly increasing incidence of cardiovascular diseases and diabetes propels the hemodialysis bloodline systems market. In 2014, data from the CDC indicated that approximately 26.7 million people, or 11.5% of U.S. adults, were diagnosed with heart disease. This significant patient population is likely to rise due to an increase in cases of advanced kidney diseases and complications. In addition, other factors such as alcohol and tobacco consumption, obesity, and genetic as well as hereditary factors are increasing the number of patients suffering from CKD. A rise in the patient pool is projected to lead to an increase in demand for drugs with greater efficacy and reduced side effects. Hence, a rise in the incidence of CKD and other forms of kidney diseases is estimated to boost the hemodialysis bloodline systems market in the near future.
The global hemodialysis bloodline systems market can be segmented based on product type, therapy type, end-user, and region. In terms of product type, the hemodialysis bloodline systems market can be divided into adult and pediatric bloodlines. Based on therapy type, the hemodialysis bloodline systems market can be segmented into double-needle therapy, single-needle therapy, single-needle cross-over, and HDF (hemodiafiltration). In terms of end-user, the global hemodialysis bloodline systems market can be classified into operating room (OR), intensive care unit (ICU), and others. Based on region, the global hemodialysis bloodline systems market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Changing demographics in emerging economies such as China, India, Brazil, and South Africa are expected to provide high growth opportunities for pharma manufacturers. Public and private health care expenditure in these countries is expected to increase. This, in turn, is likely to drive the focus of manufacturers toward these markets. For instance, according to the World Bank Group, in 2014, China’s health care expenditure was 5.5% of the GDP, and by 2020 the country’s health care expenditure is expected to double. The robust growth in health care expenditure coupled with a rise in global per capita income drives the hemodialysis bloodline systems market. Improvements in health care infrastructure and government reimbursement programs in developed as well as developing countries are likely to provide growth opportunities for the hemodialysis bloodline systems market in the near future.
Major players operating in the global hemodialysis bloodline systems market include Fresenius Medical Care, B. Braun Melsungen AG, NxStage Medical, Inc., ALLMED Medical GmbH, NIPRO Medical Corporation, and Asahi Kasei Medical Co., Ltd.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]